More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries to maintain its dominance in the GLP-1 market.

More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries to maintain its dominance in the GLP-1 market.

Indianapolis-based Eli Lilly intends to build a biomanufacturing facility that would cost $6.5 billion to build and employ 4,000+ in the greater Houston area.